These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 9839930)

  • 1. Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization.
    Durrani Z; McInerney TL; McLain L; Jones T; Bellaby T; Brennan FR; Dimmock NJ
    J Immunol Methods; 1998 Nov; 220(1-2):93-103. PubMed ID: 9839930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity.
    Devito C; Zuber B; Schröder U; Benthin R; Okuda K; Broliden K; Wahren B; Hinkula J
    J Immunol; 2004 Dec; 173(11):7078-89. PubMed ID: 15557206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric plant virus particles administered nasally or orally induce systemic and mucosal immune responses in mice.
    Brennan FR; Bellaby T; Helliwell SM; Jones TD; Kamstrup S; Dalsgaard K; Flock JI; Hamilton WD
    J Virol; 1999 Feb; 73(2):930-8. PubMed ID: 9882293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization of mice with recombinant gp41 in a systemic prime/mucosal boost protocol induces HIV-1-specific serum IgG and secretory IgA antibodies.
    Mantis NJ; Kozlowski PA; Mielcarz DW; Weissenhorn W; Neutra MR
    Vaccine; 2001 Jul; 19(28-29):3990-4001. PubMed ID: 11427275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response.
    Cleveland SM; Buratti E; Jones TD; North P; Baralle F; McLain L; McInerney T; Durrani Z; Dimmock NJ
    Virology; 2000 Jan; 266(1):66-78. PubMed ID: 10612661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus.
    McLain L; Durrani Z; Wisniewski LA; Porta C; Lomonossoff GP; Dimmock NJ
    Vaccine; 1996 Jun; 14(8):799-810. PubMed ID: 8817828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
    Staats HF; Nichols WG; Palker TJ
    J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus type 1-neutralizing antibodies raised to a glycoprotein 41 peptide expressed on the surface of a plant virus.
    McLain L; Porta C; Lomonossoff GP; Durrani Z; Dimmock NJ
    AIDS Res Hum Retroviruses; 1995 Mar; 11(3):327-34. PubMed ID: 7786579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule.
    Gherardi MM; Pérez-Jiménez E; Nájera JL; Esteban M
    J Immunol; 2004 May; 172(10):6209-20. PubMed ID: 15128809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles.
    Zhang H; Huang Y; Fayad R; Spear GT; Qiao L
    J Virol; 2004 Aug; 78(15):8342-8. PubMed ID: 15254206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.
    Borsutzky S; Fiorelli V; Ebensen T; Tripiciano A; Rharbaoui F; Scoglio A; Link C; Nappi F; Morr M; Buttó S; Cafaro A; Mühlradt PF; Ensoli B; Guzmán CA
    Eur J Immunol; 2003 Jun; 33(6):1548-56. PubMed ID: 12778472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization.
    Bradney CP; Sempowski GD; Liao HX; Haynes BF; Staats HF
    J Virol; 2002 Jan; 76(2):517-24. PubMed ID: 11752142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses.
    Sakaue G; Hiroi T; Nakagawa Y; Someya K; Iwatani K; Sawa Y; Takahashi H; Honda M; Kunisawa J; Kiyono H
    J Immunol; 2003 Jan; 170(1):495-502. PubMed ID: 12496436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate.
    Bukawa H; Sekigawa K; Hamajima K; Fukushima J; Yamada Y; Kiyono H; Okuda K
    Nat Med; 1995 Jul; 1(7):681-5. PubMed ID: 7585151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques.
    Egan MA; Chong SY; Hagen M; Megati S; Schadeck EB; Piacente P; Ma BJ; Montefiori DC; Haynes BF; Israel ZR; Eldridge JH; Staats HF
    Vaccine; 2004 Sep; 22(27-28):3774-88. PubMed ID: 15315859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract.
    Ferko B; Katinger D; Grassauer A; Egorov A; Romanova J; Niebler B; Katinger H; Muster T
    J Infect Dis; 1998 Nov; 178(5):1359-68. PubMed ID: 9780256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the ability of five adjuvants to enhance immune responses to a chimeric plant virus displaying an HIV-1 peptide.
    McInerney TL; Brennan FR; Jones TD; Dimmock NJ
    Vaccine; 1999 Mar; 17(11-12):1359-68. PubMed ID: 10195771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies.
    Zhai Y; Zhong Z; Zariffard M; Spear GT; Qiao L
    Vaccine; 2013 Nov; 31(46):5422-9. PubMed ID: 24055348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target.
    Manocha M; Pal PC; Chitralekha KT; Thomas BE; Tripathi V; Gupta SD; Paranjape R; Kulkarni S; Rao DN
    Vaccine; 2005 Dec; 23(48-49):5599-617. PubMed ID: 16099080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pseudomonas aeruginosa outer-membrane protein F epitopes are highly immunogenic in mice when expressed on a plant virus.
    Brennan FR; Jones TD; Gilleland LB; Bellaby T; Xu F; North PC; Thompson A; Staczek J; Lin T; Johnson JE; Hamilton WDO; Gilleland HE
    Microbiology (Reading); 1999 Jan; 145 ( Pt 1)():211-220. PubMed ID: 10206701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.